A Phase 3 interventional study of Ocrelizumab and Lumbar Puncture in Relapsing Multiple Sclerorsis and Multiple Sclerosis, Primary Progressive, sponsored by Genentech, Inc.. Completed at 17 sites in 4 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-06-04.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive — 2 open to participants now, 6 under way, 4 of them phase 3. ocrelizumab · Multiple Sclerosis, Chronic Progressive.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive, this one is the 6th largest by enrollment, is the only one that started in 2016, is one of 7 in phase 3, and was the 2nd registered.
245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.
Browse Multiple Sclerosis, Chronic Progressive studies →2 of the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive are open now, in 3 countries. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 8 · Phase 4 2
First in 2011; this study’s year is marked. 1 started in 2016.
This study's enrollment of 131 is above the median of 54 across 190 interventional studies indexed under Multiple Sclerosis, Chronic Progressive.
Median enrollment 184 across the 10 interventional studies. Of the 4 that completed or were terminated, 4 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche: 2 open now, 8 under way, 4 of them phase 3. Of 4 finished, 4 (100%) have results posted.
Among the 12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche, this one is the 9th largest by enrollment, is the only one that started in 2016, is one of 7 in phase 3, and was the 3rd registered.
Hoffmann-La Roche’s Multiple Sclerosis, Chronic Progressive studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 12 in Multiple Sclerosis, Chronic Progressive:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter, biomarker study designed to be hypothesis-generating in order to better understand the mechanism of action of ocrelizumab and B-cell biology in RMS or PPMS. The study will be conducted in two cohorts i.e. RMS cohort (4 arm group) and PPMS cohort (one arm group). RMS cohort: Ocrelizumab will be administered as two intravenous (IV) infusions of 300 milligrams (mg) on Days 1 and 15. Subsequent doses will be given as single 600-mg infusions at Weeks 24 and 48. Participants will be randomized in 1:1:1 ratio to receive lumbar puncture (LP) post-treatment at Week 12, 24, or 52 following the first dose of ocrelizumab in three arm groups. A fourth RMS arm with delayed treatment start (Arm 4 [control group]) will not be a part of the randomization and will be recruited separately, wherein treatment with ocrelizumab will be delayed for 12 weeks from pre-treatment baseline. PPMS cohort: Ocrelizumab 600 mg will be administered as two 300-mg IV infusions separated by 14 days at a scheduled interval of every 24 weeks. Participants will receive a LP at the start of the study before dosing with ocrelizumab and second LP at Week 52 following the first dose of ocrelizumab. A long-term extension will be conducted for participants that complete the study and continue to receive ocrelizumab. Treatment with ocrelizumab in the entire study will continue for approximately 4.5 years after the first infusion.
Inclusion Criteria:
General Inclusion Criteria:
Inclusion Criteria Specific to RMS Participants:
Inclusion Criteria Specific to RMS Cohort Arm 4 Participants:
Inclusion Criteria Specific to PPMS Participants:
Exclusion Criteria:
Exclusion Criteria Specific to RMS Participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 12. Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
Drug: Ocrelizumab · Procedure: Lumbar Puncture · Drug: Methyloprednisolone · Drug: Antihistamine
Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 24. Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
Drug: Ocrelizumab · Procedure: Lumbar Puncture · Drug: Methyloprednisolone · Drug: Antihistamine
Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
Drug: Ocrelizumab · Procedure: Lumbar Puncture · Drug: Methyloprednisolone · Drug: Antihistamine
Ocrelizumab treatment will be delayed for 12 weeks from pre-treatment baseline. Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP at Week -12 (pre-treatment baseline) and a second LP before the start of dosing (Week 1, treatment baseline). Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
Drug: Ocrelizumab · Procedure: Lumbar Puncture · Drug: Methyloprednisolone · Drug: Antihistamine
For the PPMS cohort, ocrelizumab will be administered as two 300-mg IV infusions separated by 14 days at a scheduled interval of every 24 weeks during the treatment period and then as a single 600-mg dose every 24 weeks starting week 72 during the Long-Term Extension period.
Drug: Ocrelizumab · Procedure: Lumbar Puncture · Drug: Methyloprednisolone · Drug: Antihistamine
Ocrelizumab will be administered as IV infusion.
Also known as: RO4964913
Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.
Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.
Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.
Change in Levels of NfL (Neurofilament Light) in CSF From Treatment Baseline to Post-Treatment With Ocrelizumab
Primary Analysis was based on following data-cut off: Arm 1: Baseline to post-treatment at 12 weeks Arm 2: Baseline to post-treatment at 24 weeks Arm 3: Baseline to post-treatment at 52 weeks Arm 4: Baseline to post-treatment at 12 weeks PPMS Cohort: Baseline to post-treatment at 52 weeks
Time frame: From Baseline to post-treatment (Week 12, 24, 52 according to randomization and Weeks 144 and 240)
Change in Number of CD19+ B Cells in CSF From Treatment Baseline to Post-Treatment With Ocrelizumab
Arm 1: Baseline to post-treatment at 12 weeks Arm 2: Baseline to post-treatment at 24 weeks Arm 3: Baseline to post-treatment at 52 weeks Arm 4: Baseline to post-treatment at 12 weeks PPMS Cohort: Baseline to post-treatment at 52 weeks
Time frame: From Baseline to post-treatment (Week 12, 24, 52 according to randomization and Weeks 144 and 240)
Change From Baseline in Number of CD3+ T-Cells in CSF Post-Treatment With Ocrelizumab
Arm 1: Baseline to post-treatment at 12 weeks Arm 2: Baseline to post-treatment at 24 weeks Arm 3: Baseline to post-treatment at 52 weeks Arm 4: Baseline to post-treatment at 12 weeks PPMS Cohort: Baseline to post-treatment at 52 weeks
Time frame: From Baseline to post-treatment (Week 12, 24, 52 according to randomization and Weeks 144 and 240)
131 patients enrolled at 17 study locations in the U.S., Canada, Germany, and Sweden
| Milestone | RMS Cohort Arm 1: Ocrelizumab + LP | RMS Cohort Arm 2: Ocrelizumab + LP | RMS Cohort Arm 3: Ocrelizumab + LP | RMS Cohort Arm 4: Ocrelizumab + LP | PPMS Cohort: Ocrelizumab + LP |
|---|---|---|---|---|---|
| Started | 23 | 31 | 28 | 18 | 31 |
| Completed | 0 | 0 | 0 | 0 | 1 |
| Not completed | 23 | 31 | 28 | 18 | 30 |
| Withdrew: Adverse event | 1 | 2 | 2 | 0 | 0 |
| Withdrew: Continued onto commercially available ocrelizumab | 12 | 12 | 14 | 14 | 21 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 | 1 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 3 | 1 | 0 | 1 |
| Withdrew: Other | 3 | 4 | 1 | 0 | 0 |
| Withdrew: Physician decision | 2 | 2 | 0 | 0 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 2 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 8 | 7 | 1 | 4 |
Primary Analysis was based on following data-cut off: Arm 1: Baseline to post-treatment at 12 weeks Arm 2: Baseline to post-treatment at 24 weeks Arm 3: Baseline to post-treatment at 52 weeks Arm 4: Baseline to post-treatment at 12 weeks PPMS Cohort: Baseline to post-treatment at 52 weeks
| pg/mL | RMS Cohort Arm 1: Ocrelizumab + LP | RMS Cohort Arm 2: Ocrelizumab + LP | RMS Cohort Arm 3: Ocrelizumab + LP | RMS Cohort Arm 4: Ocrelizumab + LP | PPMS Cohort: Ocrelizumab + LP |
|---|---|---|---|---|---|
| Primary Analysis | -1232.97 ± 2060.37 | -1169.13 ± 1739.49 | -1008.13 ± 1132.68 | -931.83 ± 2816.27 | 261.85 ± 1175.72 |
| LTE phase Week 144 | -2331.89 ± 3334.80 | -644.50 ± 1371.39 | -1287.58 ± 1822.72 | -2544.33 ± 3807.94 | -925.32 ± 2507.97 |
| LTE phase Week 240 | -2499.98 ± 3606.71 | -791.51 ± 1150.89 | -1060.33 ± 1678.95 | -5488.70 ± 4350.46 | -1221.33 ± 2738.19 |
Arm 1: Baseline to post-treatment at 12 weeks Arm 2: Baseline to post-treatment at 24 weeks Arm 3: Baseline to post-treatment at 52 weeks Arm 4: Baseline to post-treatment at 12 weeks PPMS Cohort: Baseline to post-treatment at 52 weeks
| cells/μL | RMS Cohort Arm 1: Ocrelizumab + LP | RMS Cohort Arm 2: Ocrelizumab + LP | RMS Cohort Arm 3: Ocrelizumab + LP | RMS Cohort Arm 4: Ocrelizumab + LP | PPMS Cohort: Ocrelizumab + LP |
|---|---|---|---|---|---|
| Primary Analysis | -0.22 ± 0.26 | -0.15 ± 0.36 | -0.13 ± 0.32 | -0.18 ± 0.37 | -0.09 ± 0.11 |
| LTE phase Week 144 | -0.11 ± 0.08 | -0.14 ± 0.20 | -0.06 ± 0.23 | 0.15 ± 0.10 | -0.01 ± 0.09 |
| LTE phase Week 240 | -0.08 ± 0.09 | -0.20 ± 0.26 | -0.02 ± 0.01 | -0.04 ± 0.05 | 0.01 ± 0.03 |
Arm 1: Baseline to post-treatment at 12 weeks Arm 2: Baseline to post-treatment at 24 weeks Arm 3: Baseline to post-treatment at 52 weeks Arm 4: Baseline to post-treatment at 12 weeks PPMS Cohort: Baseline to post-treatment at 52 weeks
| cells/μL | RMS Cohort Arm 1: Ocrelizumab + LP | RMS Cohort Arm 2: Ocrelizumab + LP | RMS Cohort Arm 3: Ocrelizumab + LP | RMS Cohort Arm 4: Ocrelizumab + LP | PPMS Cohort: Ocrelizumab + LP |
|---|---|---|---|---|---|
| Primary Analysis | -6.61 ± 10.48 | -1.92 ± 3.15 | -1.46 ± 2.67 | -1.98 ± 5.10 | -3.25 ± 4.32 |
| LTE phase Week 144 | -3.45 ± 2.33 | 1.78 ± 9.76 | -0.83 ± 4.64 | 2.25 ± 0.17 | -3.62 ± 5.56 |
| LTE phase Week 240 | -3.00 ± 3.16 | -3.47 ± 2.31 | -1.41 ± 1.30 | -1.67 ± 2.42 | -1.37 ± 0.54 |
Collected over From baseline up to 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RMS Cohort Arm 1: Ocrelizumab + LP | 1/23 (4.3%) | 5/23 (21.7%) | 23/23 (100%) |
| RMS Cohort Arm 2: Ocrelizumab + LP | 0/31 (0%) | 5/31 (16.1%) | 28/31 (90.3%) |
| RMS Cohort Arm 3: Ocrelizumab + LP | 0/28 (0%) | 1/28 (3.6%) | 27/28 (96.4%) |
| RMS Cohort Arm 4: Ocrelizumab + LP | 0/18 (0%) | 5/18 (27.8%) | 17/18 (94.4%) |
| PPMS Cohort: Ocrelizumab + LP | 1/31 (3.2%) | 9/31 (29%) | 31/31 (100%) |
| Event | RMS Cohort Arm 1: Ocrelizumab + LP | RMS Cohort Arm 2: Ocrelizumab + LP | RMS Cohort Arm 3: Ocrelizumab + LP | RMS Cohort Arm 4: Ocrelizumab + LP | PPMS Cohort: Ocrelizumab + LP |
|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 2/23 | 0/31 | 0/28 | 1/18 | 1/31 |
| COVID-19Infections and infestations | 0/23 | 1/31 | 0/28 | 1/18 | 1/31 |
| Eye injuryInjury, poisoning and procedural complications | 0/23 | 0/31 | 0/28 | 1/18 | 0/31 |
| InjuryInjury, poisoning and procedural complications | 0/23 | 0/31 | 0/28 | 1/18 | 0/31 |
| Seronegative arthritisMusculoskeletal and connective tissue disorders | 0/23 | 0/31 | 0/28 | 1/18 | 0/31 |
| Multiple sclerosis relapseNervous system disorders | 0/23 | 0/31 | 0/28 | 1/18 | 0/31 |
| CellulitisInfections and infestations | 1/23 | 0/31 | 0/28 | 0/18 | 0/31 |
| PneumoniaInfections and infestations | 1/23 | 0/31 | 0/28 | 0/18 | 1/31 |
| Completed suicidePsychiatric disorders | 1/23 | 0/31 | 0/28 | 0/18 | 0/31 |
| NeutropeniaBlood and lymphatic system disorders | 0/23 | 1/31 | 1/28 | 0/18 | 0/31 |
| Event | RMS Cohort Arm 1: Ocrelizumab + LP | RMS Cohort Arm 2: Ocrelizumab + LP | RMS Cohort Arm 3: Ocrelizumab + LP | RMS Cohort Arm 4: Ocrelizumab + LP | PPMS Cohort: Ocrelizumab + LP |
|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 7/23 | 6/31 | 10/28 | 12/18 | 13/31 |
| Infusion related reactionInjury, poisoning and procedural complications | 15/23 | 9/31 | 16/28 | 11/18 | 12/31 |
| Urinary tract infectionInfections and infestations | 4/23 | 5/31 | 5/28 | 7/18 | 11/31 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/23 | 3/31 | 4/28 | 2/18 | 11/31 |
| SinusitisInfections and infestations | 4/23 | 10/31 | 4/28 | 1/18 | 2/31 |
| Back painMusculoskeletal and connective tissue disorders | 1/23 | 0/31 | 2/28 | 4/18 | 9/31 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/23 | 1/31 | 3/28 | 2/18 | 8/31 |
| FatigueGeneral disorders | 1/23 | 2/31 | 3/28 | 4/18 | 5/31 |
| COVID-19Infections and infestations | 4/23 | 2/31 | 1/28 | 4/18 | 5/31 |
| Post lumbar puncture syndromeInjury, poisoning and procedural complications | 2/23 | 4/31 | 4/28 | 4/18 | 6/31 |
| Age, Categorical(Participants) | RMS Cohort Arm 1: Ocrelizumab + LP | RMS Cohort Arm 2: Ocrelizumab + LP | RMS Cohort Arm 3: Ocrelizumab + LP | RMS Cohort Arm 4: Ocrelizumab + LP | PPMS Cohort: Ocrelizumab + LP | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 23 | 31 | 28 | 18 | 31 | 131 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(Years) | RMS Cohort Arm 1: Ocrelizumab + LP | RMS Cohort Arm 2: Ocrelizumab + LP | RMS Cohort Arm 3: Ocrelizumab + LP | RMS Cohort Arm 4: Ocrelizumab + LP | PPMS Cohort: Ocrelizumab + LP | Total |
|---|---|---|---|---|---|---|
| Mean | 36.0 ± 10.4 | 38.7 ± 10.4 | 34.6 ± 10.8 | 36.4 ± 9.8 | 44.9 ± 7.4 | 38.5 ± 10.4 |
| Sex/Gender, Customized(Participants) | RMS Cohort Arm 1: Ocrelizumab + LP | RMS Cohort Arm 2: Ocrelizumab + LP | RMS Cohort Arm 3: Ocrelizumab + LP | RMS Cohort Arm 4: Ocrelizumab + LP | PPMS Cohort: Ocrelizumab + LP | Total |
|---|---|---|---|---|---|---|
| Male | 8 | 9 | 8 | 7 | 16 | 48 |
| Female | 15 | 22 | 20 | 11 | 15 | 83 |
| Ethnicity (NIH/OMB)(Participants) | RMS Cohort Arm 1: Ocrelizumab + LP | RMS Cohort Arm 2: Ocrelizumab + LP | RMS Cohort Arm 3: Ocrelizumab + LP | RMS Cohort Arm 4: Ocrelizumab + LP | PPMS Cohort: Ocrelizumab + LP | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 1 | 0 | 2 | 6 |
| Not Hispanic or Latino | 22 | 28 | 27 | 17 | 28 | 122 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 1 | 3 |
| Race (NIH/OMB)(Participants) | RMS Cohort Arm 1: Ocrelizumab + LP | RMS Cohort Arm 2: Ocrelizumab + LP | RMS Cohort Arm 3: Ocrelizumab + LP | RMS Cohort Arm 4: Ocrelizumab + LP | PPMS Cohort: Ocrelizumab + LP | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 3 | 1 | 3 | 0 | 9 |
| White | 21 | 28 | 25 | 13 | 29 | 116 |
| More than one race | 0 | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2016 to primary completion in Apr 2023, 83 months.
Results were first posted in Jun 2024, 1 year 1 month after primary completion.
Of 20 phase 3 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 83. This study's 83 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab
Multiple Sclerosis, Chronic Progressive →